Australia markets close in 53 minutes

CytoDyn Inc. (CYDY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
1.4700-0.0700 (-4.55%)
At close: 3:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.5400
Open1.6400
Bid0.0000 x 0
Ask0.0000 x 0
Day's range1.4500 - 1.6500
52-week range1.3500 - 7.4000
Volume2,476,295
Avg. volume2,585,100
Market cap900.926M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.2700
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • CytoDyn Receives Clearance from Brazil’s ANVISA to Commence Phase 3 Trial for Severe COVID-19 Patients
    Business Wire

    CytoDyn Receives Clearance from Brazil’s ANVISA to Commence Phase 3 Trial for Severe COVID-19 Patients

    VANCOUVER, Washington, August 03, 2021--CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Brazil’s regulatory authority ANVISA (Agência Nacional de Vigilância Sanitária) has approved the previously submitted clinical trial protocol to commence patient enrollment in its CD17 trial for severe COVID-19 patients. The Academic Research Organi

  • Business Wire

    CytoDyn Announces That Director Nominations by Rosenbaum/Patterson Activist Group Are Invalid

    VANCOUVER, Washington, August 02, 2021--CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company, announced today that the director nominations submitted by an activist group led by Paul Rosenbaum and Bruce Patterson (the "Rosenbaum/Patterson Group") were invalid. The Rosenbaum/Patterson Group attempted to nominate five director candidates to take over control of the Company’s six-member Board of Directors (the "Board").

  • CytoDyn to Hold Webcast on July 22 to Discuss Results from Cancer Trials, HIV BLA Status, NASH, and COVID-19 Trials
    GlobeNewswire

    CytoDyn to Hold Webcast on July 22 to Discuss Results from Cancer Trials, HIV BLA Status, NASH, and COVID-19 Trials

    VANCOUVER, Washington, July 19, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, and Christopher Recknor, M.D., Chief Operating Officer and Head of Clinical Development